TrialJournal of neuro-oncology2012

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

David A Reardon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.